[English] 日本語
Yorodumi
- PDB-10pj: JAK2 kinase (JH1 domain) in complex with povorcitinib -

+
Open data


ID or keywords:

Loading...

-
Basic information

Entry
Database: PDB / ID: 10pj
TitleJAK2 kinase (JH1 domain) in complex with povorcitinib
ComponentsTyrosine-protein kinase JAK2
KeywordsTRANSFERASE / Inhibitor / Kinase / Complex
Function / homology
Function and homology information


nuclear receptor-mediated mineralocorticoid signaling pathway / response to interleukin-12 / histone H3Y41 kinase activity / mammary gland epithelium development / symbiont-induced defense-related programmed cell death / positive regulation of growth hormone receptor signaling pathway / interleukin-35-mediated signaling pathway / positive regulation of growth factor dependent skeletal muscle satellite cell proliferation / granulocyte macrophage colony-stimulating factor receptor complex / regulation of postsynapse to nucleus signaling pathway ...nuclear receptor-mediated mineralocorticoid signaling pathway / response to interleukin-12 / histone H3Y41 kinase activity / mammary gland epithelium development / symbiont-induced defense-related programmed cell death / positive regulation of growth hormone receptor signaling pathway / interleukin-35-mediated signaling pathway / positive regulation of growth factor dependent skeletal muscle satellite cell proliferation / granulocyte macrophage colony-stimulating factor receptor complex / regulation of postsynapse to nucleus signaling pathway / granulocyte-macrophage colony-stimulating factor signaling pathway / thrombopoietin-mediated signaling pathway / interleukin-12 receptor complex / Signaling by Erythropoietin / interleukin-23 receptor complex / Erythropoietin activates STAT5 / collagen-activated signaling pathway / interleukin-12 receptor binding / activation of Janus kinase activity / Erythropoietin activates Phospholipase C gamma (PLCG) / post-embryonic hemopoiesis / positive regulation of NK T cell proliferation / type 1 angiotensin receptor binding / positive regulation of T-helper 17 type immune response / positive regulation of MHC class II biosynthetic process / erythropoietin-mediated signaling pathway / Interleukin-23 signaling / positive regulation of cell-substrate adhesion / interleukin-12-mediated signaling pathway / positive regulation of leukocyte proliferation / positive regulation of platelet activation / positive regulation of natural killer cell proliferation / interleukin-23-mediated signaling pathway / intrinsic apoptotic signaling pathway in response to oxidative stress / interleukin-3-mediated signaling pathway / positive regulation of epithelial cell apoptotic process / interleukin-5-mediated signaling pathway / Interleukin-12 signaling / acetylcholine receptor binding / cellular response to interleukin-3 / positive regulation of platelet aggregation / Signaling by Leptin / IL-6-type cytokine receptor ligand interactions / Interleukin-27 signaling / Interleukin-35 Signalling / growth hormone receptor binding / axon regeneration / regulation of nitric oxide biosynthetic process / response to hydroperoxide / negative regulation of cell-cell adhesion / growth hormone receptor signaling pathway / extrinsic component of plasma membrane / regulation of receptor signaling pathway via JAK-STAT / Interleukin-20 family signaling / platelet-derived growth factor receptor signaling pathway / extrinsic component of cytoplasmic side of plasma membrane / Interleukin-6 signaling / IFNG signaling activates MAPKs / Erythropoietin activates Phosphoinositide-3-kinase (PI3K) / enzyme-linked receptor protein signaling pathway / interleukin-6-mediated signaling pathway / positive regulation of tyrosine phosphorylation of STAT protein / peptide hormone receptor binding / MAPK3 (ERK1) activation / positive regulation of interleukin-17 production / MAPK1 (ERK2) activation / Prolactin receptor signaling / cellular response to dexamethasone stimulus / mesoderm development / negative regulation of cardiac muscle cell apoptotic process / signaling receptor activator activity / positive regulation of SMAD protein signal transduction / Interleukin-3, Interleukin-5 and GM-CSF signaling / growth hormone receptor signaling pathway via JAK-STAT / insulin receptor substrate binding / response to tumor necrosis factor / Interleukin receptor SHC signaling / Regulation of IFNG signaling / type II interferon-mediated signaling pathway / Growth hormone receptor signaling / extrinsic apoptotic signaling pathway / positive regulation of vascular associated smooth muscle cell proliferation / cell surface receptor signaling pathway via JAK-STAT / phosphatidylinositol 3-kinase binding / Erythropoietin activates RAS / Signaling by CSF3 (G-CSF) / lipopolysaccharide-mediated signaling pathway / actin filament polymerization / positive regulation of T cell proliferation / negative regulation of cytokine production involved in inflammatory response / negative regulation of protein localization to chromatin / post-translational protein modification / SH2 domain binding / positive regulation of apoptotic signaling pathway / erythrocyte differentiation / Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants / endosome lumen / tumor necrosis factor-mediated signaling pathway / positive regulation of interleukin-1 beta production / positive regulation of receptor signaling pathway via JAK-STAT
Similarity search - Function
Tyrosine-protein kinase, non-receptor Jak2 / Janus kinase 2, pseudokinase domain / Janus kinase 2, catalytic domain / Tyrosine-protein kinase JAK2, SH2 domain / JAK2, FERM domain C-lobe / Tyrosine-protein kinase, non-receptor Jak/Tyk2 / JAK, FERM F2 lobe domain / FERM F1 lobe ubiquitin-like domain / JAK1-3/TYK2, pleckstrin homology-like domain / : ...Tyrosine-protein kinase, non-receptor Jak2 / Janus kinase 2, pseudokinase domain / Janus kinase 2, catalytic domain / Tyrosine-protein kinase JAK2, SH2 domain / JAK2, FERM domain C-lobe / Tyrosine-protein kinase, non-receptor Jak/Tyk2 / JAK, FERM F2 lobe domain / FERM F1 lobe ubiquitin-like domain / JAK1-3/TYK2, pleckstrin homology-like domain / : / Jak1 pleckstrin homology-like domain / FERM F2 acyl-CoA binding protein-like domain / FERM F1 ubiquitin-like domain / SH2 domain / FERM central domain / FERM superfamily, second domain / FERM domain / FERM domain profile. / Band 4.1 domain / Band 4.1 homologues / Src homology 2 (SH2) domain profile. / Src homology 2 domains / SH2 domain / SH2 domain superfamily / Tyrosine-protein kinase, catalytic domain / Tyrosine kinase, catalytic domain / Tyrosine protein kinases specific active-site signature. / PH-like domain superfamily / Tyrosine-protein kinase, active site / Protein tyrosine and serine/threonine kinase / Serine-threonine/tyrosine-protein kinase, catalytic domain / Protein kinase, ATP binding site / Protein kinases ATP-binding region signature. / Protein kinase domain profile. / Protein kinase domain / Protein kinase-like domain superfamily
Similarity search - Domain/homology
: / MALONIC ACID / Tyrosine-protein kinase JAK2
Similarity search - Component
Biological speciesHomo sapiens (human)
MethodX-RAY DIFFRACTION / SYNCHROTRON / MOLECULAR REPLACEMENT / Resolution: 1.59 Å
AuthorsEpling, L.B. / Fenalti, G.
Funding support United States, 1items
OrganizationGrant numberCountry
Other private United States
CitationJournal: J.Med.Chem. / Year: 2026
Title: Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune Diseases.
Authors: Zhuo, J. / Li, Y.L. / Qian, D.Q. / Burns, D.M. / Mei, S. / Rafalski, M. / Xu, M. / Cao, G. / Pan, Y. / Jia, Z. / Jalluri, R. / Epling, L.B. / Fenalti, G. / Deller, M.C. / Procak, J. / ...Authors: Zhuo, J. / Li, Y.L. / Qian, D.Q. / Burns, D.M. / Mei, S. / Rafalski, M. / Xu, M. / Cao, G. / Pan, Y. / Jia, Z. / Jalluri, R. / Epling, L.B. / Fenalti, G. / Deller, M.C. / Procak, J. / Covington, M. / He, X. / Collins, R. / Stubbs, M. / Burke, K. / Oliver, J. / Margulis, A. / Boer, J. / Wynn, R. / Scherle, P. / Diamond, S. / Newton, R. / Zhang, Y. / Metcalf, B. / Yao, W.
History
DepositionJan 30, 2026Deposition site: RCSB / Processing site: RCSB
Revision 1.0Jun 10, 2026Provider: repository / Type: Initial release
Revision 1.1Jun 17, 2026Group: Database references / Category: citation
Item: _citation.journal_volume / _citation.page_first / _citation.page_last

-
Structure visualization

Structure viewerMolecule:
MolmilJmol/JSmol

Downloads & links

-
Assembly

Deposited unit
A: Tyrosine-protein kinase JAK2
B: Tyrosine-protein kinase JAK2
hetero molecules


Theoretical massNumber of molelcules
Total (without water)75,6565
Polymers74,5372
Non-polymers1,1193
Water12,178676
1
A: Tyrosine-protein kinase JAK2
hetero molecules


Theoretical massNumber of molelcules
Total (without water)37,8803
Polymers37,2681
Non-polymers6122
Water181
TypeNameSymmetry operationNumber
identity operation1_555x,y,z1
MethodPISA
2
B: Tyrosine-protein kinase JAK2
hetero molecules


Theoretical massNumber of molelcules
Total (without water)37,7762
Polymers37,2681
Non-polymers5071
Water181
TypeNameSymmetry operationNumber
identity operation1_555x,y,z1
MethodPISA
Unit cell
Length a, b, c (Å)99.610, 69.132, 110.326
Angle α, β, γ (deg.)90.000, 99.519, 90.000
Int Tables number5
Space group name H-MI121
Space group name HallC2y(x,y,-x+z)
Symmetry operation#1: x,y,z
#2: -x,y,-z
#3: x+1/2,y+1/2,z+1/2
#4: -x+1/2,y+1/2,-z+1/2
Components on special symmetry positions
IDModelComponents
11B-2189-

HOH

-
Components

#1: Protein Tyrosine-protein kinase JAK2 / Janus kinase 2 / JAK-2


Mass: 37268.285 Da / Num. of mol.: 2 / Fragment: JH1 domain
Source method: isolated from a genetically manipulated source
Source: (gene. exp.) Homo sapiens (human) / Gene: JAK2 / Production host: Spodoptera frugiperda (fall armyworm)
References: UniProt: O60674, non-specific protein-tyrosine kinase
#2: Chemical ChemComp-MLA / MALONIC ACID / DICARBOXYLIC ACID C3 / PROPANEDIOLIC ACID / METHANEDICARBOXYLIC ACID


Mass: 104.061 Da / Num. of mol.: 1 / Source method: obtained synthetically / Formula: C3H4O4
#3: Chemical ChemComp-A1C68 / 4-{3-(cyanomethyl)-3-[(4M)-3',5'-dimethyl-1H,1'H-[4,4'-bipyrazol]-1-yl]azetidin-1-yl}-2,5-difluoro-N-[(2S)-1,1,1-trifluoropropan-2-yl]benzamide


Mass: 507.459 Da / Num. of mol.: 2 / Source method: obtained synthetically / Formula: C23H22F5N7O / Feature type: SUBJECT OF INVESTIGATION
#4: Water ChemComp-HOH / water


Mass: 18.015 Da / Num. of mol.: 676 / Source method: isolated from a natural source / Formula: H2O
Has ligand of interestY
Has protein modificationY

-
Experimental details

-
Experiment

ExperimentMethod: X-RAY DIFFRACTION / Number of used crystals: 1

-
Sample preparation

CrystalDensity Matthews: 2.51 Å3/Da / Density % sol: 51.06 %
Crystal growTemperature: 293 K / Method: vapor diffusion, sitting drop
Details: 100 mM MD - Buffer System 6 pH 8.0, 1.4 M Na2-Malonate pH 6.0

-
Data collection

DiffractionMean temperature: 100 K / Serial crystal experiment: N
Diffraction sourceSource: SYNCHROTRON / Site: PETRA III, EMBL c/o DESY / Beamline: P13 (MX1) / Wavelength: 0.97626 Å
DetectorType: DECTRIS EIGER X 16M / Detector: PIXEL / Date: Dec 13, 2024
RadiationProtocol: SINGLE WAVELENGTH / Monochromatic (M) / Laue (L): M / Scattering type: x-ray
Radiation wavelengthWavelength: 0.97626 Å / Relative weight: 1
ReflectionResolution: 1.59→33.78 Å / Num. obs: 93036 / % possible obs: 93.2 % / Redundancy: 7 % / Biso Wilson estimate: 13.54 Å2 / CC1/2: 1 / Rmerge(I) obs: 0.1 / Rpim(I) all: 0.06 / Rrim(I) all: 0.12 / Net I/σ(I): 9
Reflection shellResolution: 1.59→1.72 Å / Redundancy: 7.3 % / Rmerge(I) obs: 0.65 / Mean I/σ(I) obs: 2.3 / Num. unique obs: 9767 / CC1/2: 0.92 / Rpim(I) all: 0.39 / Rrim(I) all: 0.76 / % possible all: 98.5

-
Processing

Software
NameVersionClassification
PHENIX1.21.2_5419refinement
autoPROCdata reduction
SCALAdata scaling
PHASERphasing
RefinementMethod to determine structure: MOLECULAR REPLACEMENT / Resolution: 1.59→33.78 Å / SU ML: 0.1921 / Cross valid method: FREE R-VALUE / σ(F): 1.35 / Phase error: 27.1772
Stereochemistry target values: GeoStd + Monomer Library + CDL v1.2
RfactorNum. reflection% reflection
Rfree0.2307 4602 4.96 %
Rwork0.2006 88221 -
obs0.2022 92823 92.98 %
Solvent computationShrinkage radii: 0.9 Å / VDW probe radii: 1.1 Å / Solvent model: FLAT BULK SOLVENT MODEL
Displacement parametersBiso mean: 20.52 Å2
Refinement stepCycle: LAST / Resolution: 1.59→33.78 Å
ProteinNucleic acidLigandSolventTotal
Num. atoms4964 0 79 676 5719
Refine LS restraints
Refine-IDTypeDev idealNumber
X-RAY DIFFRACTIONf_bond_d0.01355427
X-RAY DIFFRACTIONf_angle_d1.47027398
X-RAY DIFFRACTIONf_chiral_restr0.0867772
X-RAY DIFFRACTIONf_plane_restr0.0165948
X-RAY DIFFRACTIONf_dihedral_angle_d6.5859841
LS refinement shell
Resolution (Å)Rfactor RfreeNum. reflection RfreeRfactor RworkNum. reflection RworkRefine-ID% reflection obs (%)
1.59-1.60.3161270.26383057X-RAY DIFFRACTION98
1.6-1.620.28181840.2573126X-RAY DIFFRACTION98.92
1.62-1.640.2921790.23733071X-RAY DIFFRACTION97.95
1.64-1.660.23841460.23523111X-RAY DIFFRACTION98.88
1.66-1.690.23361660.23393100X-RAY DIFFRACTION98.14
1.69-1.710.25931620.23773114X-RAY DIFFRACTION99.42
1.71-1.730.29621080.26082109X-RAY DIFFRACTION66.28
1.73-1.760.3321740.23473075X-RAY DIFFRACTION99.33
1.76-1.790.24011750.23653113X-RAY DIFFRACTION98.74
1.79-1.820.29261370.22313173X-RAY DIFFRACTION99.04
1.82-1.850.26071740.2123092X-RAY DIFFRACTION99.15
1.85-1.880.23971650.21383097X-RAY DIFFRACTION98.64
1.88-1.910.23561100.20782121X-RAY DIFFRACTION80.17
1.92-1.960.26271140.20472057X-RAY DIFFRACTION73.79
1.96-20.25011710.20473086X-RAY DIFFRACTION98.79
2-2.050.21721430.19963072X-RAY DIFFRACTION96.81
2.05-2.10.22221070.2042194X-RAY DIFFRACTION69.39
2.1-2.150.24131680.19323134X-RAY DIFFRACTION99.55
2.15-2.220.20261630.19493156X-RAY DIFFRACTION99.4
2.22-2.290.22311230.19172685X-RAY DIFFRACTION84.45
2.29-2.370.23061570.20373191X-RAY DIFFRACTION99.85
2.37-2.470.25891540.20693155X-RAY DIFFRACTION99.85
2.47-2.580.24851550.20833172X-RAY DIFFRACTION99.91
2.58-2.710.23071380.20492659X-RAY DIFFRACTION83.94
2.71-2.880.23221860.20843124X-RAY DIFFRACTION99.82
2.88-3.110.22691600.20273198X-RAY DIFFRACTION99.76
3.11-3.420.22141590.17863171X-RAY DIFFRACTION99.64
3.42-3.880.18081510.162458X-RAY DIFFRACTION82.41
3.92-4.920.18471630.15483177X-RAY DIFFRACTION99.29
4.93-33.780.22171830.21363173X-RAY DIFFRACTION97.36

+
About Yorodumi

-
News

-
Feb 9, 2022. New format data for meta-information of EMDB entries

New format data for meta-information of EMDB entries

  • Version 3 of the EMDB header file is now the official format.
  • The previous official version 1.9 will be removed from the archive.

Related info.:EMDB header

External links:wwPDB to switch to version 3 of the EMDB data model

-
Aug 12, 2020. Covid-19 info

Covid-19 info

URL: https://pdbj.org/emnavi/covid19.php

New page: Covid-19 featured information page in EM Navigator.

Related info.:Covid-19 info / Mar 5, 2020. Novel coronavirus structure data

+
Mar 5, 2020. Novel coronavirus structure data

Novel coronavirus structure data

Related info.:Yorodumi Speices / Aug 12, 2020. Covid-19 info

External links:COVID-19 featured content - PDBj / Molecule of the Month (242)：Coronavirus Proteases

+
Jan 31, 2019. EMDB accession codes are about to change! (news from PDBe EMDB page)

EMDB accession codes are about to change! (news from PDBe EMDB page)

  • The allocation of 4 digits for EMDB accession codes will soon come to an end. Whilst these codes will remain in use, new EMDB accession codes will include an additional digit and will expand incrementally as the available range of codes is exhausted. The current 4-digit format prefixed with “EMD-” (i.e. EMD-XXXX) will advance to a 5-digit format (i.e. EMD-XXXXX), and so on. It is currently estimated that the 4-digit codes will be depleted around Spring 2019, at which point the 5-digit format will come into force.
  • The EM Navigator/Yorodumi systems omit the EMD- prefix.

Related info.:Q: What is EMD? / ID/Accession-code notation in Yorodumi/EM Navigator

External links:EMDB Accession Codes are Changing Soon! / Contact to PDBj

+
Jul 12, 2017. Major update of PDB

Major update of PDB

  • wwPDB released updated PDB data conforming to the new PDBx/mmCIF dictionary.
  • This is a major update changing the version number from 4 to 5, and with Remediation, in which all the entries are updated.
  • In this update, many items about electron microscopy experimental information are reorganized (e.g. em_software).
  • Now, EM Navigator and Yorodumi are based on the updated data.

External links:wwPDB Remediation / Enriched Model Files Conforming to OneDep Data Standards Now Available in the PDB FTP Archive

-
Yorodumi

Thousand views of thousand structures

  • Yorodumi is a browser for structure data from EMDB, PDB, SASBDB, etc.
  • This page is also the successor to EM Navigator detail page, and also detail information page/front-end page for Omokage search.
  • The word "yorodu" (or yorozu) is an old Japanese word meaning "ten thousand". "mi" (miru) is to see.

Related info.:EMDB / PDB / SASBDB / Comparison of 3 databanks / Yorodumi Search / Aug 31, 2016. New EM Navigator & Yorodumi / Yorodumi Papers / Jmol/JSmol / Function and homology information / Changes in new EM Navigator and Yorodumi

Read more